News
Public · Published
Citigroup maintains Gilead Sciences at Buy, raises price target to $188 from $165
Citigroup kept its Buy rating on Gilead Sciences and raised its price target to $188 from $165, a 13.9% increase. The new target implies 10.1% upside from the October 30 close of $170.68.
Published:
Updated:
What happened
Citigroup kept its Buy rating on Gilead Sciences and raised its price target to $188 from $165, a 13.9% increase. The new target implies 10.1% upside from the October 30 close of $170.68.
Confirmed
Global impact / market context
A higher price target signals that Citigroup expects Gilead shares to be worth more than before. Because the firm still rates the stock Buy, the change suggests analysts see room for further gains, which may draw more investor attention to the shares.
Analyst inference
Other recent analyst notes on Gilead cluster between $175 and $200, above the $170.68 close. That range suggests broad analyst confidence in the stock, though each target reflects separate assumptions about future revenue and costs rather than a single agreed view.
Analyst inference
What to watch
- Five analyst notes over the past 30 days set Gilead price targets from $175 to $200, so watch whether new targets stay in that range. Confirmed
- Watch whether Gilead reports revenue and profit results that support the higher expectations behind targets like Citigroup's $188, since targets are forecasts, not results. Proposed
- If more analysts raise targets, investor demand for Gilead shares could grow, potentially lifting the price toward those levels; cuts could do the opposite. Analyst inference
Evidence
- Original source link unavailable